Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:BUX NYSE:CRL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$159.78-2.4%$144.87$91.86▼$254.15$8.04B1.491.03 million shs518,978 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International-2.36%+1.69%+5.80%+60.49%-21.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.5568 of 5 stars2.15.00.04.72.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.25Hold$174.549.24% UpsideCurrent Analyst Ratings BreakdownLatest OBJ, BUX, BD1, and CRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$170.00 ➝ $180.007/9/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$150.00 ➝ $200.005/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.94$21.19 per share7.54$67.80 per share2.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$0.65N/A14.535.54-0.66%15.19%6.93%8/6/2025 (Estimated)Latest OBJ, BUX, BD1, and CRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CRLCharles River Laboratories International$2.50N/AN/AN/A$983.76 millionN/A5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.781.431.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%Insider OwnershipCompanyInsider OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International20,10049.12 million48.48 millionOptionableOBJ, BUX, BD1, and CRL HeadlinesRecent News About These CompaniesLaurus Global Equity Management Inc. Buys 11,030 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)2 hours ago | marketbeat.comCharles River Laboratories International (NYSE:CRL) Upgraded by Citigroup to Buy RatingJuly 12 at 2:17 AM | americanbankingnews.comCharles River Laboratories International, Inc. (NYSE:CRL) Receives $171.85 Average Target Price from BrokeragesJuly 10 at 3:19 AM | americanbankingnews.comCharles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Iridian Asset Management LLC CTJuly 9 at 10:14 AM | marketbeat.comCharles River Laboratories International (NYSE:CRL) Price Target Raised to $180.00 at Evercore ISIJuly 9 at 9:48 AM | marketbeat.comCharles River Laboratories International (NYSE:CRL) Upgraded at CitigroupJuly 9 at 8:39 AM | marketbeat.comCharles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Financial Counselors Inc.July 9 at 5:41 AM | marketbeat.comDAVENPORT & Co LLC Has $237,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)July 9 at 3:54 AM | marketbeat.comCharles River Laboratories International Inc. - CRL | Barron'sJuly 8, 2025 | barrons.com23,395 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Acquired by Pekin Hardy Strauss Inc.July 7, 2025 | marketbeat.comVontobel Holding Ltd. Grows Stake in Charles River Laboratories International, Inc. (NYSE:CRL)July 7, 2025 | marketbeat.comCharles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of "Hold" from AnalystsJuly 7, 2025 | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Cuts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)July 6, 2025 | marketbeat.comNew York State Teachers Retirement System Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)July 6, 2025 | marketbeat.comCharles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 6, 2025 | marketbeat.comCharles River Laboratories International (NYSE:CRL) Rating Lowered to Hold at Wall Street ZenJuly 5, 2025 | marketbeat.comKBC Group NV Sells 9,056 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)July 2, 2025 | marketbeat.comBessemer Group Inc. Sells 16,538 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)July 1, 2025 | marketbeat.comAsset Management One Co. Ltd. Has $224,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)July 1, 2025 | marketbeat.comCharles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Allspring Global Investments Holdings LLCJune 28, 2025 | marketbeat.comCharles River Laboratories International (NYSE:CRL) Downgraded by Wall Street Zen to "Hold"June 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseStarbucks Stock: Culture Fix May Be Key to Long-Term GrowthBy Chris Markoch | June 12, 2025View Starbucks Stock: Culture Fix May Be Key to Long-Term GrowthOBJ, BUX, BD1, and CRL Company DescriptionsBiomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$159.78 -3.88 (-2.37%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$159.44 -0.33 (-0.21%) As of 07/11/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
